Resolutions from Zealand Pharma's Annual General Meeting 2026

Core Points - Zealand Pharma held its Annual General Meeting (AGM) on March 26, 2026, in a hybrid format, approving all proposals except for the non-binding advisory vote on the remuneration report [2][3] Financial Performance - The AGM acknowledged the management's report and approved the audited Annual Report for 2025, which showed a net profit after tax of TDKK 6,455,008, to be carried forward to the next financial year [3] Board Elections and Composition - Existing board members were re-elected, and Iris Löw-Friedrich was newly elected to the Board of Directors, while Jeffrey Berkowitz and Bernadette Mary Connaughton did not stand for re-election [4] - The Board of Directors constituted itself with Martin Nicklasson as Chair and Kirsten Aarup Drejer as Vice-Chair [5] Committees - The Audit Committee will include Martin Nicklasson and Leonard Kruimer, with Leonard Kruimer as Chair [5] - The Remuneration Committee will consist of Enrique Conterno Martinelli and Iris Löw-Friedrich, chaired by Martin Nicklasson [5] - The Scientific Committee will include Elaine Sullivan, Enrique Conterno Martinelli, and Iris Löw-Friedrich, chaired by Kirsten Aarup Drejer [6] - The Nomination Committee will consist of Leonard Kruimer and Martin Nicklasson, chaired by Kirsten Aarup Drejer [6] Auditor - PricewaterhouseCoopers (PwC) was re-elected as the auditor for both financial and sustainability reporting [7] Share Buyback Authorization - The Board of Directors was authorized to acquire treasury shares up to 10% of the Company's share capital, with specific conditions regarding financing and pricing [9] Remuneration Report - The non-binding advisory vote on the Remuneration Report did not receive sufficient support for approval [10] Board Fees - The fees for the Board of Directors for the financial year 2026 were approved and remain unchanged from 2025 [11] Company Overview - Zealand Pharma is a biotechnology company focused on advancing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise [13] - The company has over 10 drug candidates in clinical development, with two products on the market and three in late-stage development [14]